Latent Tuberculosis Infection (LTBI) and Its Potential Targets: An Investigation into Dormant Phase Pathogens

Area of Science:

• Microbiology and Infectious Diseases
• Drug Discovery and Development
• Molecular Biology

Background:

• Latent tuberculosis infection (LTBI) is a significant global health challenge, with one-third of the world's population infected.
• Reactivation of LTBI poses a continuous risk, necessitating improved therapeutic strategies beyond current first-line treatments.
• The identification of novel drug targets for dormant Mycobacterium tuberculosis bacilli is a critical research priority.

Purpose of the Study:

• To review the current understanding of tuberculosis infection, focusing on the dormant phase of the bacilli.
• To provide insights into potential molecular targets for novel antitubercular therapies.
• To summarize preclinical and clinical advancements and emerging approaches in antitubercular drug discovery.

Main Methods:

• Comprehensive literature review of scientific publications on tuberculosis infection, diagnostics, and drug discovery.
• Analysis of current research on molecular targets associated with dormant Mycobacterium tuberculosis.
• Synthesis of information on preclinical and clinical studies of novel antitubercular agents.

Main Results:

• Detailed overview of LTBI, its diagnostic challenges, and the biological characteristics of dormant bacilli.
• Identification and explanation of several potential molecular targets within dormant tuberculosis bacilli.
• Summary of the current landscape of antitubercular drug development, including preclinical and clinical findings.

Conclusions:

• Novel therapeutic targets and drug discovery approaches are crucial for combating latent tuberculosis infection effectively.
• Further research into the molecular mechanisms of dormant bacilli is essential for developing next-generation TB therapies.
• The review highlights promising avenues for future drug development to address the global burden of LTBI.